{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:29:14Z","timestamp":1786768154515,"version":"build-2736575974"},"reference-count":35,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health and Welfare","award":["MOHW113-TDU-B-221-134007"],"award-info":[{"award-number":["MOHW113-TDU-B-221-134007"]}]},{"award":["MOHW113-TDU-B-221-134007"],"award-info":[{"award-number":["MOHW113-TDU-B-221-134007"]}],"id":[{"id":"https:\/\/ror.org\/024w0ge69","id-type":"ROR","asserted-by":"publisher"}]},{"name":"National Science and Technology Council","award":["NSTC 112-2314-B-075A-010-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-075A-010-MY3"]}]},{"award":["NSTC 112-2314-B-075A-010-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-075A-010-MY3"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1140402C"],"award-info":[{"award-number":["TCVGH-1140402C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-VTA114V112"],"award-info":[{"award-number":["TCVGH-VTA114V112"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1140402B"],"award-info":[{"award-number":["TCVGH-1140402B"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1150401C"],"award-info":[{"award-number":["TCVGH-1150401C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"award":["TCVGH-1140402C"],"award-info":[{"award-number":["TCVGH-1140402C"]}],"id":[{"id":"https:\/\/ror.org\/00e87hq62","id-type":"ROR","asserted-by":"publisher"}]},{"award":["TCVGH-VTA114V112"],"award-info":[{"award-number":["TCVGH-VTA114V112"]}],"id":[{"id":"https:\/\/ror.org\/00e87hq62","id-type":"ROR","asserted-by":"publisher"}]},{"award":["TCVGH-1140402B"],"award-info":[{"award-number":["TCVGH-1140402B"]}],"id":[{"id":"https:\/\/ror.org\/00e87hq62","id-type":"ROR","asserted-by":"publisher"}]},{"award":["TCVGH-1150401C"],"award-info":[{"award-number":["TCVGH-1150401C"]}],"id":[{"id":"https:\/\/ror.org\/00e87hq62","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Tenofovir alafenamide (TAF) and entecavir (ETV) are recommended alternatives to tenofovir disoproxil fumarate (TDF) for patients with chronic hepatitis B (CHB) at increased risk of kidney injury. However, data from direct head-to-head comparisons of their long-term renal safety and antiviral efficacy after switching from TDF are lacking. We aimed to compare these outcomes between TAF and ETV. Methods: This multicenter retrospective cohort study included consecutive CHB patients who switched from TDF to either TAF or ETV between January 2012 and December 2021. Inverse probability of treatment weighting using the propensity score was applied to balance the baseline characteristics. Changes in estimated glomerular filtration rate (eGFR) were assessed using a linear mixed-effects model. Renal dysfunction was defined as a decline of at least one GFR category. Results: A total of 235 patients were included (TAF, n = 168; ETV, n = 67). After adjustment for key risk factors, the mean eGFR decline over 36 months was not significantly different between the TAF and ETV groups (\u22123.21 mL\/min\/1.73 m2 [95% CI, \u22124.98 to \u22121.44] vs. \u22123.49 mL\/min\/1.73 m2 [95% CI, \u22129.49 to \u22122.50]; p = 0.856). The 3-year cumulative incidence of renal dysfunction was also not significantly different between groups (16.6% [95% CI, 10.5\u201323.3] vs. 7.8% [95% CI, 2.7\u201316.2]; p = 0.135). Alanine aminotransferase normalization rates (83.0% vs. 78.8%; p = 0.575) and virological suppression rates (97.8% vs. 97.1%; p = 1.000) were similarly high in both groups. Conclusions: TAF and ETV demonstrated similar long-term renal safety and antiviral efficacy, supporting both agents as reasonable switch options for CHB patients requiring TDF discontinuation because of renal safety concerns.<\/jats:p>","DOI":"10.3390\/jcm15166257","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:06:16Z","timestamp":1786608376000},"page":"6257","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tenofovir Alafenamide Versus Entecavir as Switch Therapy After Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B"],"prefix":"10.3390","volume":"15","author":[{"given":"Hsin-Ju","family":"Tsai","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407219, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402202, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407219, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yueh","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi 600566, Taiwan"},{"name":"Department of Sport, Leisure and Health Management, Tainan University of Technology, Tainan City 710302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chang","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407219, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402202, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Cheng","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407219, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402202, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-2665","authenticated-orcid":false,"given":"Shou-Wu","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407219, Taiwan"},{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Sheng","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407219, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Chun","family":"Peng","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407219, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-4315","authenticated-orcid":false,"given":"Teng-Yu","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407219, Taiwan"},{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S2468-1253(24)00089-X","article-title":"WHO 2024 hepatitis B guidelines: An opportunity to transform care","volume":"9","author":"Easterbrook","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 83, 502\u2013583."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/apt.14682","article-title":"Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients","volume":"47","author":"Tsai","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/apt.14945","article-title":"Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment","volume":"48","author":"Wong","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.cgh.2018.08.037","article-title":"Changes in Renal Function in Patients with Chronic HBV Infection Treated with Tenofovir Disoproxil Fumarate vs Entecavir","volume":"17","author":"Trinh","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/jvh.13603","article-title":"Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease","volume":"28","author":"Tsai","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/apt.17819","article-title":"Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment","volume":"59","author":"Hong","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: A review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/hep.27730","article-title":"Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection","volume":"62","author":"Hwang","year":"2015","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: A randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/apt.70327","article-title":"Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment","volume":"63","author":"Wong","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Liu, C.J., Lim, Y.S., Chen, C.Y., Chen, C.H., Huang, Y.H., Lin, C.Y., Lin, C.C., Yu, M.L., Abramov, F., and Yee, L.J. (2025). Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal\/hepatic impairment: Phase 2 study sub-analysis from Taiwan. J. Formos. Med. Assoc., in press.","DOI":"10.1016\/j.jfma.2025.07.023"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.31793","article-title":"Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch from Tenofovir Disoproxil Fumarate in Routine Practice","volume":"74","author":"Toyoda","year":"2021","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching from Tenofovir Disoproxil Fumarate","volume":"20","author":"Byun","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/jmv.27863","article-title":"Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate","volume":"94","author":"Liang","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/jgh.16593","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B","volume":"39","author":"Nam","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1111\/jgh.70059","article-title":"Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment","volume":"40","author":"Ogawa","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/liv.14017","article-title":"Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir","volume":"39","author":"Vigano","year":"2019","journal-title":"Liver Int."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/liv.15208","article-title":"Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B","volume":"42","author":"Jung","year":"2022","journal-title":"Liver Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/apt.17532","article-title":"Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy","volume":"58","author":"Lee","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race","volume":"385","author":"Inker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"(2024). Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"c109","DOI":"10.1159\/000145453","article-title":"Outcomes of stage 3-5 chronic kidney disease before end-stage renal disease at a single center in Taiwan","volume":"109","author":"Chiu","year":"2008","journal-title":"Nephron Clin. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and Functional Changes with the Aging Kidney","volume":"23","author":"Denic","year":"2016","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/apt.15020","article-title":"Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment","volume":"48","author":"Udompap","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jhep.2024.12.009","article-title":"All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease","volume":"83","author":"Huang","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6257\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:14:46Z","timestamp":1786767286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":35,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166257"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166257","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}